Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.

Importance: Ficlatuzumab can be used to treat head and neck squamous cell carcinoma (HNSCC) by inhibiting c-Met receptor-mediated cell proliferation, migration, and invasion.

Objective: To understand the effect of ficlatuzumab on HNSCC proliferation, migration, and invasion.

Design, Setting, And Participants: The effects of ficlatuzumab on HNSCC proliferation, invasion, and migration were tested.